The All Ordinaries Index (ASX: XAO) is up 0.6% in morning trade, with this ASX All Ords healthcare share charging ahead of those gains.
The outperforming stock in question is clinical dermatology company Botanix Pharmaceuticals Ltd (ASX: BOT).
Botanix shares closed yesterday trading for 45 cents. In late morning trade on Wednesday, shares are changing hands for 46 cents apiece, up 2.2%.
This outperformance is nothing new for the ASX All Ords healthcare share.
Over the past 12 months, for example, the All Ords has gained a slender 0.3%, while Botanix shares have surged 89.6%.
And Seneca Financial Solutions' Arthur Garipoli forecasts more potential outsized gains ahead (courtesy of The Bull).
ASX All Ords healthcare share with a 'big sales opportunity'
"This clinical dermatology company has shipped its Sofdra topical gel to first patients, a prescription medicine used to treat axillary hyperhidrosis (excessive underarm sweating)," said Garipoli, who has a buy recommendation on the ASX All Ords healthcare share.
Citing the first reason Botanix shares are a buy, he said, "Sofdra has been approved by the US Food and Drug Administration."
That FDA approval opens the door to a huge market for the company's product.
As for the second reason the stock looks like a good buy right now, Garipoli said:
The company has embarked on a commercial launch of Sofdra with an experienced US based team. The company recently announced the product launch has so far proven to be successful.
With FDA approval in the bag, and the initial product rollout going well, the third reason Garipoli is bullish on Botanix is the company's large potential sales pipeline.
"The huge target market provides Botanix with a potentially big sales opportunity going forward," he said.
What's the latest from Botanix Pharmaceuticals?
On 11 March, the ASX All Ords healthcare share held a commercial update conference.
The company reported that there are 10 million people in the US with axillary hyperhidrosis, with 3.7 million of those people currently seeking treatment.
Botanix said it will focus on those patients seeking treatment with its targeted sales force. But the company also aims to capture some of the 6.3 million patients not actively seeking treatment via digital messaging.
Botanix shares could also catch some tailwinds from the stock's 24 March addition to the S&P/ASX 300 Index (ASX: XKO). That came as part of the S&P Dow Jones Indices quarterly review and followed the big increase in the company's market cap over the prior year.
With the ASX All Ords healthcare share now also an ASX 300 stock, it opens the door for more fund managers and index tracking funds to buy the stock.
